Malignant Peripheral Nerve Sheath Tumor disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MPNST MCID: MLG077 MIFTS: 62	Malignant Peripheral Nerve Sheath Tumor (MPNST) Categories: Cancer diseases, Neuronal diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Malignant Peripheral Nerve Sheath Tumor

MalaCards integrated aliases for Malignant Peripheral Nerve Sheath Tumor:

Name: Malignant Peripheral Nerve Sheath Tumor ¹¹ ¹⁹ ⁵⁸ ¹⁴ ¹⁶ ⁷¹ ⁷⁵

Malignant Neurilemmoma ¹⁹ ⁵⁸ ⁵³

Neurofibrosarcoma ¹⁹ ⁵⁸ ⁷¹

Mpnst ¹⁹ ⁵⁸ ⁵³

Malignant Neurofibroma ¹⁹ ⁵⁸

Malignant Schwannoma ¹⁹ ⁵⁸

Neurogenic Sarcoma ¹⁹ ⁵⁸

Malignant Neoplasm of the Peripheral Nerve Sheath ¹¹

Malignant Peripheral Nerve Sheath Tumors ⁵³

Schwannoma, Malignant ⁷⁵

Characteristics:

Prevelance:

1-9/100000 (Worldwide) ⁵⁸

Age Of Onset:

Adolescent,Adult,Childhood,Elderly,Infancy ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Neoplasms

Malignant neoplasms of mesothelial and soft tissue

Malignant neoplasm of peripheral nerves and autonomic nervous system

Malignant neoplasm: Peripheral nerves and autonomic nervous system, unspecified

Orphanet: ⁵⁸

Rare neurological diseases

External Ids:

Disease Ontology ¹¹ DOID:5940

MeSH ⁴³ D018319

NCIt ⁴⁹ C3798

SNOMED-CT ⁶⁸ 134324009

ICD10 via Orphanet ³² C47.9

UMLS via Orphanet ⁷² C0206729 C0751690

Orphanet ⁵⁸ ORPHA3148

EFO ¹⁶ EFO_0000760

UMLS ⁷¹ C0206729 C0751690

Sources

Summaries for Malignant Peripheral Nerve Sheath Tumor

GARD: ¹⁹ A Malignant peripheral nerve sheath tumor (MPNST) is a tumor that develops in the protective lining that covers nerves. The first symptom of MPNST is often a lump or mass that increases in size, sometimes causing pain or a tingling sensation. MPNST is considered an aggressive tumor because there is up to a 65% chance of the tumor regrowing after surgery (a recurrence), and approximately 40% chance of spreading to distant parts of the body (a metastasis), most commonly to the lung. Approximately 25-50% of MPNSTs are associated with a genetic condition known as neurofibromatosis type 1.

MalaCards based summary: Malignant Peripheral Nerve Sheath Tumor, also known as malignant neurilemmoma, is related to malignant triton tumor and epithelioid malignant peripheral nerve sheath tumor. An important gene associated with Malignant Peripheral Nerve Sheath Tumor is NF1 (Neurofibromin 1), and among its related pathways/superpathways are Apoptotic Pathways in Synovial Fibroblasts and Disease. The drugs Doxorubicin and Mechlorethamine have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and small intestine, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Decreased viability

Orphanet: ⁵⁸ Malignant peripheral nerve sheath tumor (MPNST) is a rare and often aggressive soft tissue sarcoma occurring in a wide range of anatomical sites.

Wikipedia ⁷⁵ Malignant peripheral nerve sheath tumor: A malignant peripheral nerve sheath tumor (MPNST) is a form of cancer of the connective tissue... more...

Schwannoma, malignant: A neurofibroma is a benign nerve-sheath tumor in the peripheral nervous system. In 90% of cases, they... more...

Sources

Related Diseases for Malignant Peripheral Nerve Sheath Tumor

Diseases in the Benign Peripheral Nerve Sheath Tumor family:

Malignant Peripheral Nerve Sheath Tumor

Diseases related to Malignant Peripheral Nerve Sheath Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 724)

#	Related Disease	Score	Top Affiliating Genes
1	malignant triton tumor	33.2	SOX10 NF1 MYOG CD34
2	epithelioid malignant peripheral nerve sheath tumor	33.1	SOX10 NF1 MYOG CD34
3	malignant glandular tumor of peripheral nerve sheath	32.8	SOX10 NF1 MYOG
4	neurofibrosarcoma	32.7	TP53 SOX10 NF2 NF1 KIT CDKN2A
5	lipofibromatosis-like neural tumor	32.4	SOX10 CD34
6	neurofibromatosis	32.2	TP53 PDGFRA NF2 NF1 KIT EGFR
7	neurofibromatosis, type i	31.7	TP53 S100B PDGFRA NF2 NF1 KIT
8	acoustic neuroma	31.5	NF2 NF1 CD44
9	sarcoma	31.3	VIM TP53 S100B S100A1 PDGFRA MYOG
10	neurilemmoma	31.2	VIM SOX10 S100B S100A1 PDGFRA NF2
11	orbital cancer	31.1	NF2 NF1 CD34
12	neurofibroma	31.1	VIM TP53 SOX10 S100B S100A1 PDGFRA
13	lung benign neoplasm	31.1	TP53 MET EGFR CDKN2A
14	fibrosarcoma	31.1	VIM TP53 PDGFRA KIT EGFR ACTC1
15	connective tissue benign neoplasm	31.0	TP53 SOX10 NF1 MDM2 KIT CD34
16	pheochromocytoma	31.0	VIM S100B NF1 KIT CDKN2A CD44
17	cellular schwannoma	31.0	SOX10 NF2 NF1 KIT CD34
18	mesothelioma, malignant	31.0	VIM NF2 MET CDKN2A
19	rhabdoid cancer	31.0	VIM TP53 ACTC1
20	ocular melanoma	31.0	NF1 KIT CDKN2A
21	skin benign neoplasm	31.0	TP53 NF1 CD34
22	neurilemmomatosis	31.0	SOX10 NF2 NF1 CDKN2A
23	malignant spindle cell melanoma	30.9	TP53 SOX10 NF1 KIT CDKN2A CD34
24	epidural spinal canal neoplasm	30.9	NF2 NF1 CD34
25	plexiform neurofibroma	30.9	TP53 SOX10 S100B PDGFRA NF2 NF1
26	perineurioma	30.9	VIM S100B NF2 KIT CD34 ACTC1
27	monophasic synovial sarcoma	30.9	SOX10 MYOG CD34
28	atypical neurofibroma	30.9	TP53 SOX10 NF2 NF1 CDKN2A
29	fibrous histiocytoma	30.8	VIM SOX10 S100B CD34 ACTC1
30	bap1 tumor predisposition syndrome	30.8	TP53 NF2 NF1 MET KIT EGFR
31	peritoneal mesothelioma	30.8	TP53 NF2 CDKN2A
32	sarcoma, synovial	30.8	VIM S100B NF1 MYOG MET MDM2
33	penile cancer	30.8	TP53 EGFR CDKN2A
34	cholecystitis	30.8	TP53 EGFR CDKN2A
35	carney complex variant	30.7	TP53 NF2 NF1
36	angiosarcoma	30.7	VIM PDGFRA MDM2 KIT CD34 ACTC1
37	cutaneous fibrous histiocytoma	30.7	SOX10 S100B S100A1 CD34 ACTC1
38	plexiform schwannoma	30.7	SOX10 NF2 NF1 KIT CD34
39	neurilemmoma of the fifth cranial nerve	30.7	NF2 NF1 CD34
40	vulva cancer	30.7	TP53 KIT EGFR CDKN2A
41	laryngeal benign neoplasm	30.7	TP53 EGFR CDKN2A CD44
42	blastoma	30.7	TP53 S100B MYOG KIT EGFR
43	mesenchymal cell neoplasm	30.7	TP53 PDGFRA NF1 MYOG MDM2 KIT
44	granular cell tumor	30.7	VIM S100B S100A1
45	thymoma	30.7	TP53 KIT EGFR CDKN2A
46	sarcomatoid squamous cell skin carcinoma	30.6	SOX10 MYOG CD34
47	b-lymphoblastic leukemia/lymphoma	30.6	KIT CDKN2A CD34
48	diffuse astrocytoma	30.6	TP53 PDGFRA NF1 EGFR CDKN2A
49	prostate sarcoma	30.6	MYOG CD34
50	cowden syndrome	30.6	TP53 NF2 NF1 EGFR CDKN2A

Graphical network of the top 20 diseases related to Malignant Peripheral Nerve Sheath Tumor:

Sources

Symptoms & Phenotypes for Malignant Peripheral Nerve Sheath Tumor

GenomeRNAi Phenotypes related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

²⁵ (show all 49)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-10	10.45	MET
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-105	10.45	VIM
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-107	10.45	MET
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-115	10.45	SOX10
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-119	10.45	MET
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-121	10.45	EGFR
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-152	10.45	KIT
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-157	10.45	KIT
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-170	10.45	KIT
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-177	10.45	SOX10 VIM
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-18	10.45	SOX10
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-185	10.45	MET
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-189	10.45	VIM
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-191	10.45	MET
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-201	10.45	MET
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-21	10.45	EGFR
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-213	10.45	S100B
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-214	10.45	EGFR
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-30	10.45	KIT
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-38	10.45	MET
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-4	10.45	MET
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-43	10.45	EGFR
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-48	10.45	S100B
24	Increased shRNA abundance (Z-score > 2)	GR00366-A-49	10.45	SOX10
25	Increased shRNA abundance (Z-score > 2)	GR00366-A-61	10.45	KIT
26	Increased shRNA abundance (Z-score > 2)	GR00366-A-63	10.45	MET VIM
27	Increased shRNA abundance (Z-score > 2)	GR00366-A-66	10.45	S100B
28	Increased shRNA abundance (Z-score > 2)	GR00366-A-80	10.45	MET
29	Increased shRNA abundance (Z-score > 2)	GR00366-A-81	10.45	SOX10
30	Increased shRNA abundance (Z-score > 2)	GR00366-A-85	10.45	EGFR KIT MET SOX10
31	Increased shRNA abundance (Z-score > 2)	GR00366-A-9	10.45	KIT
32	Increased shRNA abundance (Z-score > 2)	GR00366-A-91	10.45	EGFR SOX10
33	Increased shRNA abundance (Z-score > 2)	GR00366-A-99	10.45	KIT
34	Decreased viability	GR00055-A-1	10.32	EGFR
35	Decreased viability	GR00055-A-2	10.32	EGFR
36	Decreased viability	GR00173-A	10.32	PDGFRA
37	Decreased viability	GR00221-A-1	10.32	CDKN2A EGFR KIT NF1 PDGFRA
38	Decreased viability	GR00221-A-2	10.32	NF1
39	Decreased viability	GR00221-A-3	10.32	CDKN2A PDGFRA
40	Decreased viability	GR00221-A-4	10.32	CDKN2A EGFR NF1 PDGFRA
41	Decreased viability	GR00249-S	10.32	NF1 PDGFRA
42	Decreased viability	GR00301-A	10.32	KIT
43	Decreased viability	GR00386-A-1	10.32	NF1
44	Decreased viability	GR00402-S-2	10.32	PDGFRA
45	no effect	GR00402-S-1	10.18	ACTC1 CD34 CDKN2A EGFR KIT MDM2
46	no effect	GR00402-S-2	10.18	ACTC1 CD34 CD44 CDKN2A EGFR KIT
47	Reduced mammosphere formation	GR00396-S	9.5	CD34 CD44 EGFR MDM2 MMP13 TOP2A
48	Increased cell migration	GR00055-A-1	9.26	NF1
49	Increased cell migration	GR00055-A-3	9.26	NF1

MGI Mouse Phenotypes related to Malignant Peripheral Nerve Sheath Tumor:

⁴⁵ (show all 26)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.57	ACTC1 CD34 CD44 CDKN2A EGFR KIT
2	normal	MP:0002873	10.46	ACTC1 CD44 EGFR KIT MDM2 MET
3	growth/size/body region	MP:0005378	10.46	ACTC1 CD44 CDKN2A EGFR KIT MDM2
4	nervous system	MP:0003631	10.45	ACTC1 CD44 CDKN2A EGFR KIT MDM2
5	muscle	MP:0005369	10.44	ACTC1 CD44 CDKN2A EGFR KIT MDM2
6	cellular	MP:0005384	10.42	ACTC1 CD34 CD44 CDKN2A EGFR KIT
7	neoplasm	MP:0002006	10.4	CD34 CD44 CDKN2A EGFR KIT MDM2
8	endocrine/exocrine gland	MP:0005379	10.36	CD44 CDKN2A EGFR KIT MDM2 MET
9	behavior/neurological	MP:0005386	10.36	ACTC1 CD44 CDKN2A KIT MDM2 MET
10	embryo	MP:0005380	10.35	CDKN2A EGFR KIT MDM2 MET MYOG
11	pigmentation	MP:0001186	10.33	CD44 CDKN2A EGFR KIT MDM2 NF1
12	cardiovascular system	MP:0005385	10.32	ACTC1 CD44 CDKN2A EGFR KIT MDM2
13	renal/urinary system	MP:0005367	10.3	CD44 EGFR KIT MDM2 MET NF1
14	liver/biliary system	MP:0005370	10.28	CD44 CDKN2A EGFR KIT MDM2 MET
15	limbs/digits/tail	MP:0005371	10.27	CD44 EGFR KIT MDM2 MET MMP13
16	no phenotypic analysis	MP:0003012	10.26	CDKN2A EGFR KIT MDM2 MET MYOG
17	digestive/alimentary	MP:0005381	10.26	CD44 CDKN2A EGFR KIT MDM2 MET
18	immune system	MP:0005387	10.25	CD34 CD44 CDKN2A EGFR KIT MDM2
19	respiratory system	MP:0005388	10.25	CD44 CDKN2A EGFR KIT MET MYOG
20	reproductive system	MP:0005389	10.15	CD44 CDKN2A EGFR KIT MDM2 NF1
21	craniofacial	MP:0005382	10.11	EGFR KIT MDM2 MET NF1 NF2
22	skeleton	MP:0005390	10.06	CD44 CDKN2A EGFR KIT MDM2 MMP13
23	vision/eye	MP:0005391	10	CD44 CDKN2A EGFR KIT MET NF1
24	hematopoietic system	MP:0005397	9.93	ACTC1 CD34 CD44 CDKN2A EGFR KIT
25	mortality/aging	MP:0010768	9.86	ACTC1 CD44 CDKN2A EGFR KIT MDM2
26	integument	MP:0010771	9.53	CD34 CD44 CDKN2A EGFR KIT MDM2

Sources

Drugs & Therapeutics for Malignant Peripheral Nerve Sheath Tumor

Drugs for Malignant Peripheral Nerve Sheath Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 92)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Doxorubicin

Approved, Investigational

Phase 2, Phase 3

23214-92-8

31703

Mechlorethamine

Approved, Investigational

Phase 2, Phase 3

51-75-2

4033

Cyclophosphamide

Approved, Investigational

Phase 2, Phase 3

50-18-0, 6055-19-2

2907

Ifosfamide

Approved

Phase 2, Phase 3

3778-73-2

3690

Daunorubicin

Approved

Phase 2, Phase 3

20830-81-3

30323

Palifosfamide

Investigational

Phase 2, Phase 3

31645-39-3

100427

Anti-Bacterial Agents

Phase 2, Phase 3

Antibiotics, Antitubercular

Phase 2, Phase 3

Liposomal doxorubicin

Phase 2, Phase 3

Alkylating Agents

Phase 2, Phase 3

Antineoplastic Agents, Alkylating

Phase 2, Phase 3

Protein Kinase Inhibitors

Phase 2, Phase 3

Imatinib Mesylate

Phase 2, Phase 3

220127-57-1

Coenzyme M

Approved, Investigational

Phase 2

3375-50-6

598 23662354

Sorafenib

Approved, Investigational

Phase 2

284461-73-0

216239

Dacarbazine

Approved, Investigational

Phase 2

4342-03-4

2942 5351166

Adenosine

Approved, Investigational

Phase 2

58-61-7

60961

Trastuzumab

Approved, Investigational

Phase 2

180288-69-1

Romidepsin

Approved, Investigational

Phase 2

128517-07-7

5352062

Xylometazoline

Approved, Investigational

Phase 1, Phase 2

526-36-3

5709

Dasatinib

Approved, Investigational

Phase 2

302962-49-8

3062316

Everolimus

Approved

Phase 2

159351-69-6

70789204 6442177

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

135329020

Lenograstim

Approved, Investigational

Phase 2

135968-09-1

Erlotinib

Approved, Investigational

Phase 2

183319-69-9, 183321-74-6

176870

Melphalan

Approved

Phase 2

148-82-3

4053 460612

Fludarabine

Approved

Phase 2

75607-67-9, 21679-14-1

30751 657237

Etoposide

Approved

Phase 2

33419-42-0

36462

Picropodophyllin

Approved, Investigational

Phase 2

518-28-5, 477-47-4

10607 72435

Thiotepa

Approved, Investigational

Phase 2

52-24-4

5453

Mycophenolic acid

Approved, Investigational

Phase 2

24280-93-1

446541

Tacrolimus

Approved, Investigational

Phase 2

104987-11-3

6473866 445643

Nivolumab

Approved

Phase 2

946414-94-4

Ipilimumab

Approved

Phase 2

477202-00-9

Decitabine

Approved, Investigational

Phase 2

2353-33-5

451668

Pancrelipase

Approved, Investigational

Phase 1, Phase 2

53608-75-6

8519

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 2

23593-75-1

2812

Dexrazoxane

Approved, Withdrawn

Phase 2

24584-09-6

71384

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

5284616 6436030

Durvalumab

Approved, Investigational

Phase 2

1428935-60-7

Gemcitabine

Approved

Phase 1, Phase 2

95058-81-4, 122111-03-9

60750

Docetaxel

Approved, Investigational

Phase 1, Phase 2

114977-28-5

148124

Pembrolizumab

Approved

Phase 2

1374853-91-4

254741536

D-Phenylalanine

Approved, Experimental, Investigational, Nutraceutical

Phase 2

63-91-2, 673-06-3

6140 71567

D-Tyrosine

Approved, Experimental, Investigational, Nutraceutical

Phase 1, Phase 2

133585-56-5, 60-18-4, 556-02-5

1153 6057

D-Threonine

Approved, Experimental, Nutraceutical

Phase 2

72-19-5, 632-20-2

205 6288

Lorvotuzumab mertansine

Investigational

Phase 2

1008106-64-6

Ado-Trastuzumab Emtansine

Phase 2

Maytansine

Phase 2

Interventional clinical trials:

(show top 50) (show all 57)

#	Name	Status	NCT ID	Phase	Drugs
1	Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age	Completed	NCT00346164	Phase 3	doxorubicin hydrochloride;ifosfamide
2	Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)	Active, not recruiting	NCT02180867	Phase 2, Phase 3	Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
3	An Open-label Multicenter Phase II Study of Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors	Terminated	NCT00427583	Phase 2, Phase 3	imatinib mesylate
4	Hypofractionated 5x5 Gy Radiotherapy With Sequential Doxorubicin and Ifosfamide-based Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall	Unknown status	NCT03651375	Phase 2	Sequential chemotherapy - 3 courses of AI
5	Phase II Trial of Sorafenib and Dacarbazine in Soft Tissue Sarcoma	Completed	NCT00837148	Phase 2	Sorafenib and Dacarbazine
6	A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors	Completed	NCT01614795	Phase 2	Temsirolimus
7	A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; NSC#: 783609) in Children With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma	Completed	NCT02452554	Phase 2
8	Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma	Completed	NCT01653028	Phase 2	Alisertib
9	A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas	Completed	NCT01154452	Phase 1, Phase 2	Gamma-Secretase Inhibitor RO4929097;Vismodegib
10	A Randomized, Double-Blind Phase II, Study of Gemcitabine Alone or in Combination With Pazopanib for Refractory Soft Tissue Sarcoma	Completed	NCT01532687	Phase 2	Gemcitabine;Gemcitabine Hydrochloride;Pazopanib;Pazopanib Hydrochloride
11	A Multicenter Phase II Study of Sorafenib (BAY43-9006) in Non-GIST Sarcomas	Completed	NCT00245102	Phase 2	sorafenib tosylate
12	A Phase II Study of Single Agent Depsipeptide (FK228) in Metastatic or Unresectable Soft Tissue Sarcomas	Completed	NCT00112463	Phase 2	romidepsin
13	A Phase I/II Trial of Ganetespib in Combination With the mTOR Inhibitor Sirolimus for Patients With Recurrent or Refractory Sarcomas Including Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors	Completed	NCT02008877	Phase 1, Phase 2	ganetespib;Sirolimus
14	A Phase II Trial of Dasatinib in Advanced Sarcomas	Completed	NCT00464620	Phase 2	Dasatinib
15	Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors	Completed	NCT01661283	Phase 2	everolimus;bevacizumab
16	Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Malignant Peripheral Nerve Sheath Tumors	Completed	NCT00304083	Phase 2	doxorubicin hydrochloride;etoposide;ifosfamide
17	U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II	Completed	NCT00068367	Phase 2	erlotinib hydrochloride
18	A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric and Adolescent-Young Adults Patients With High Risk Solid Tumors	Recruiting	NCT04530487	Phase 2	Cyclosporine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil;Tacrolimus;Thiotepa
19	DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors	Recruiting	NCT02834013	Phase 2
20	A Phase II Study of ASTX727 in Patients With PRC2 Loss Malignant Peripheral Nerve Sheath Tumor (MPNST)	Recruiting	NCT04872543	Phase 2	ASTX727
21	Phase I Study Evaluating Combination Therapy With the Receptor Tyrosine Kinase Inhibitor PLX3397 and Sirolimus in Patients With Unresectable Sarcoma and Phase II Study in Malignant Peripheral Nerve Sheath Tumors	Recruiting	NCT02584647	Phase 1, Phase 2	PLX3397;Sirolimus
22	A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With MTAP Homozygous Deletion	Recruiting	NCT05245500	Phase 1, Phase 2	MRTX1719
23	A Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors	Recruiting	NCT03611868	Phase 1, Phase 2	APG-115+Pembrolizumab
24	Phase 2 Study Using Tazemetostat in Patients With Recurrent/Refractory and/or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST)	Recruiting	NCT04917042	Phase 2	Tazemetostat
25	Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis (Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors)	Recruiting	NCT05011019	Phase 1, Phase 2	AL2846 capsules
26	A Non-Inferiority Study of Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma	Active, not recruiting	NCT02584309	Phase 2	Dexrazoxane;Doxorubicin
27	A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors	Active, not recruiting	NCT03872427	Phase 2	Telaglenastat Hydrochloride
28	Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas	Active, not recruiting	NCT03989596	Phase 2
29	SARC031: A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination With the mTOR Inhibitor Sirolimus for Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors	Active, not recruiting	NCT03433183	Phase 2	Selumetinib;Sirolimus
30	A Phase 1/2 Open Label, Basket Study to Assess the Safety, Tolerability and Anti-Tumor Activity of Afamitresgene Autoleucel in Pediatric Subjects With MAGE-A4 Positive Tumors	Not yet recruiting	NCT05642455	Phase 1, Phase 2
31	A Phase 1/2 Trial of the MEK Inhibitor Selumetinib and Bromodomain Inhibitor With Durvalumab (MEDI4736), a PD-L1 Antibody for Sarcomas Including Malignant Peripheral Nerve Sheath Tumors (NF112)	Not yet recruiting	NCT05253131	Phase 2	Selumetinib
32	A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma	Terminated	NCT02601209	Phase 1, Phase 2	Pazopanib;Pazopanib Hydrochloride;Sapanisertib
33	A Phase IB/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)	Terminated	NCT01418001	Phase 1, Phase 2	Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination
34	A Phase II Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery	Terminated	NCT02691026	Phase 2	Pembrolizumab
35	A Phase 2 Study of CPI-0610, a Small Molecule Inhibitor of Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Malignant Peripheral Nerve Sheath Tumors	Withdrawn	NCT02986919	Phase 2	CPI-0610
36	A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma	Completed	NCT00720174	Phase 1	Doxorubicin Hydrochloride
37	A Phase I Dose Escalation Study of Intratumoral or Intravenous Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory Non-Central Nervous System (Non-CNS) Solid Tumors	Completed	NCT00931931	Phase 1
38	Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1: Clinical, Histopathologic, and Genomic Analysis	Completed	NCT02211768	Phase 1	[18F]-FLT-PET/CT scans
39	A Randomized Trial of Filgrastim-SD/01 vs. Filgrastim in Newly Diagnosed Children and Young Adults With Sarcoma Treated With Dose-Intensive Chemotherapy	Completed	NCT00004853	Phase 1
40	Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Unresectable or Recurrent Malignant Peripheral Nerve Sheath Tumor	Recruiting	NCT02700230	Phase 1
41	First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors	Recruiting	NCT04222413	Phase 1	Metarrestin
42	A Phase 1 Study of Metronomic Selinexor in Select Soft Tissue Sarcomas and Split Dosing of Selinexor in All Soft Tissue Sarcomas	Recruiting	NCT04811196	Phase 1	Selinexor
43	Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor	Recruiting	NCT04465643	Phase 1	Nivolumab;Ipilimumab
44	Phase I Study of B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults	Recruiting	NCT04483778	Phase 1
45	B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)	Recruiting	NCT04897321	Phase 1	Fludarabine;Cyclophosphamide;MESNA;B7-H3 CAR T cells
46	Phase I Study of EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults	Recruiting	NCT03618381	Phase 1
47	A Phase 1B Study of Ribociclib in Combination With Doxorubicin in Advanced Soft Tissue Sarcomas	Active, not recruiting	NCT03009201	Phase 1	Doxorubicin Hydrochloride;Ribociclib
48	A Phase I Study of Nivolumab and Intratumoral BO 112 for Resectable Soft Tissue Sarcoma	Active, not recruiting	NCT04420975	Phase 1
49	A Phase I Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of TQ-B3234 Capsules in Chinese Patients With Type I Neurofibromatosis (Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors)	Not yet recruiting	NCT05107037	Phase 1	TQ-B3234 capsule
50	A Phase I Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor in Combination With the Proteasome Inhibitor Ixazomib for the Treatment of Advanced Sarcoma	Withdrawn	NCT03880123	Phase 1	Selinexor;Ixazomib

Search NIH Clinical Center for Malignant Peripheral Nerve Sheath Tumor

Sources

Genetic Tests for Malignant Peripheral Nerve Sheath Tumor

Sources

Anatomical Context for Malignant Peripheral Nerve Sheath Tumor

Organs/tissues related to Malignant Peripheral Nerve Sheath Tumor:

MalaCards : Lung, T Cells, Small Intestine, Spinal Cord, Lymph Node, Breast, Bone

Sources

Publications for Malignant Peripheral Nerve Sheath Tumor

Articles related to Malignant Peripheral Nerve Sheath Tumor:

(show top 50) (show all 3747)

#	Title	Authors	PMID	Year
1	Malignant peripheral nerve sheath tumor of intracranial nerve: a case series review. ⁵³ ⁶²	Ziadi A...Saliba I	20399579	2010
2	The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo. ⁵³ ⁶²	Banerjee S...Gutmann DH	20124472	2010
3	Tyrosine kinase expression in pulmonary metastases and paired primary tumors. ⁵³ ⁶²	Muehling BM...Sunder-Plassmann L	19948538	2010
4	Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft. ⁵³ ⁶²	Bhola P...Guha A	19634141	2010
5	Establishment and characterization of a novel human malignant peripheral nerve sheath tumor cell line, FMS-1, that overexpresses epidermal growth factor receptor and cyclooxygenase-2. ⁵³ ⁶²	Hakozaki M...Abe M	19921253	2009
6	Malignant peripheral nerve sheath tumor of the uterine cervix expressing both S-100 protein and HMB-45. ⁵³ ⁶²	Kim NR...Ha SY	20025639	2009
7	Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells. ⁵³ ⁶²	Eckert JM...Carroll SL	19306381	2009
8	Expression and significance of EGFR in malignant peripheral nerve sheath tumor. ⁵³ ⁶²	Keizman D...Merimsky O	19330289	2009
9	Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides. ⁵³ ⁶²	Slomiany MG...Toole BP	19470767	2009
10	Molecular characterization of permanent cell lines from primary, metastatic and recurrent malignant peripheral nerve sheath tumors (MPNST) with underlying neurofibromatosis-1. ⁵³ ⁶²	Fang Y...Jhanwar SC	19414372	2009
11	Actin expression in neural crest cell-derived tumors including schwannomas, malignant peripheral nerve sheath tumors, neurofibromas and melanocytic tumors. ⁵³ ⁶²	Dundr P...Tvrdik D	19154261	2009
12	EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. ⁵³ ⁶²	Holtkamp N...von Deimling A	18650488	2008
13	Expression of S100A6 protein in a broad spectrum of cutaneous tumors using tissue microarrays. ⁵³ ⁶²	Fullen DR...Thomas D	18201235	2008
14	Differential expression of S100 protein subtypes in malignant melanoma, and benign and malignant peripheral nerve sheath tumors. ⁵³ ⁶²	Nonaka D...Rubin BP	18547346	2008
15	Immunohistochemical study of GLUT-1 in oral peripheral nerve sheath tumors. ⁵³ ⁶²	Salla JT...Mesquita RA	18826382	2008
16	Sox10: a pan-schwannian and melanocytic marker. ⁵³ ⁶²	Nonaka D...Rubin BP	18636017	2008
17	Diagnostic implications of podoplanin expression in peripheral nerve sheath neoplasms. ⁵³ ⁶²	Jokinen CH...Rubin BP	18480004	2008
18	DNA copy number changes in high-grade malignant peripheral nerve sheath tumors by array CGH. ⁵³ ⁶²	Kresse SH...Meza-Zepeda LA	18522746	2008
19	Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors. ⁵³ ⁶²	Tawbi H...Baker LH	18448562	2008
20	Telomerase activity is a biomarker for high grade malignant peripheral nerve sheath tumors in neurofibromatosis type 1 individuals. ⁵³ ⁶²	Mantripragada KK...Upadhyaya M	18069666	2008
21	High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization. ⁵³ ⁶²	Mantripragada KK...Upadhyaya M	18281533	2008
22	Malignant peripheral nerve sheath tumor of the breast: case report. ⁵³ ⁶²	Dhingra KK...Khurana N	18154670	2007
23	Primary pulmonary malignant peripheral nerve sheath tumor: a case report. ⁵³ ⁶²	Tashiro T...Sano N	17910355	2007
24	MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. ⁵³ ⁶²	Holtkamp N...von Deimling A	17786186	2007
25	Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB. ⁵³ ⁶²	Aoki M...Iwasaki H	17558420	2007
26	Low grade malignant peripheral nerve sheath tumor with smooth muscle differentiation. ⁵³ ⁶²	Rodriguez FJ...Erlandson RA	17119986	2007
27	Mice with GFAP-targeted loss of neurofibromin demonstrate increased axonal MET expression with aging. ⁵³ ⁶²	Su W...Sherman LS	17348023	2007
28	Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. ⁵³ ⁶²	Ambrosini G...Schwartz GK	17146434	2007
29	Nestin expression as a new marker in malignant peripheral nerve sheath tumors. ⁵³ ⁶²	Shimada S...Illei PB	17300669	2007
30	Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. ⁵³ ⁶²	Mahller YY...Cripe TP	17235305	2007
31	Somatic alterations of the NF1 gene in an NF1 individual with multiple benign tumours (internal and external) and malignant tumour types. ⁵³ ⁶²	Spurlock G...Upadhyaya M	17551851	2007
32	Reconstitution of the NF1 GAP-related domain in NF1-deficient human Schwann cells. ⁵³ ⁶²	Thomas SL...De Vries GH	16908010	2006
33	Identification of a novel amplicon at distal 17q containing the BIRC5/SURVIVIN gene in malignant peripheral nerve sheath tumours. ⁵³ ⁶²	Storlazzi CT...Mertens F	16721726	2006
34	Functional analysis and molecular modeling show a preserved wild-type activity of p53(C238Y). ⁵³ ⁶²	Ferrone M...Pilotti S	16818505	2006
35	Cluster analysis of immunohistochemical profiles in synovial sarcoma, malignant peripheral nerve sheath tumor, and Ewing sarcoma. ⁵³ ⁶²	Olsen SH...Lucas DR	16528378	2006
36	Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. ⁵³ ⁶²	Miller SJ...Ratner N	16510576	2006
37	Calretinin expression in tumors of adipose tissue. ⁵³ ⁶²	Cates JM...Black CC	16613326	2006
38	Loss of p16 (INK4A) expression is associated with allelic imbalance/loss of heterozygosity of chromosome 9p21 in microdissected malignant peripheral nerve sheath tumors. ⁵³ ⁶²	Sabah M...Kay E	16540739	2006
39	Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. ⁵³ ⁶²	Holtkamp N...von Deimling A	16357008	2006
40	Malignant peripheral nerve sheath tumor arising from the colon in a newborn: report of a case and review of the literatures. ⁵³ ⁶²	Lee YJ...Jung EJ	16481232	2006
41	c-Kit receptor expression in normal human Schwann cells and Schwann cell lines derived from neurofibromatosis type 1 tumors. ⁵³ ⁶²	Dang I...DeVries GH	16235251	2005
42	Apolipoprotein D is down-regulated during malignant transformation of neurofibromas. ⁵³ ⁶²	Hunter S...Varma V	16153462	2005
43	Activation of the neuregulin-1/ErbB signaling pathway promotes the proliferation of neoplastic Schwann cells in human malignant peripheral nerve sheath tumors. ⁵³ ⁶²	Stonecypher MS...Carroll SL	15897877	2005
44	FNAC diagnosis of MPNST--a case report. ⁵³ ⁶²	Yadavrao KA...Kanthirav KG	16761762	2005
45	ATP-binding cassette superfamily transporter gene expression in human soft tissue sarcomas. ⁵³ ⁶²	Oda Y...Tsuneyoshi M	15609299	2005
46	Schwann cell lines derived from malignant peripheral nerve sheath tumors respond abnormally to platelet-derived growth factor-BB. ⁵³ ⁶²	Dang I...DeVries GH	15602756	2005
47	Tumor suppressor mutations and growth factor signaling in the pathogenesis of NF1-associated peripheral nerve sheath tumors: II. The role of dysregulated growth factor signaling. ⁵³ ⁶²	Carroll SL...Stonecypher MS	15715079	2005
48	[Morphology and immunohistochemical characteristics of hepatic primary and metastatic malignant spindle cell tumors]. ⁵³ ⁶²	Liang YM...Zhong M	15774214	2005
49	Apo D in soft tissue tumors: a novel marker for dermatofibrosarcoma protuberans. ⁵³ ⁶²	West RB...Lui CL	15252314	2004
50	Genetic and phenotypic characterization of tumor cells derived from malignant peripheral nerve sheath tumors of neurofibromatosis type 1 patients. ⁵³ ⁶²	Frahm S...Kluwe L	15207265	2004

Sources

Genes for Malignant Peripheral Nerve Sheath Tumor

Genes related to Malignant Peripheral Nerve Sheath Tumor (0 elite genes):

(show all 35)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	NF1	Neurofibromin 1	Protein Coding	37.84	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10534774 17348023 19414372 (more) 9354454 16908010 12296648 20124472 12152785 10469433 15602756 11406645 10812008 12432832 10362810 16761762 12810251 17551851 13679444 19634141 12612091
2	VIM	Vimentin	Protein Coding	35.61	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17725305 11580072 16481232 (more) 11732802 18154670
3	NF2	NF2, Moesin-Ezrin-Radixin Like (MERLIN) Tumor Suppressor	Protein Coding	31.29	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10403310 20399579 12152785 (more) 12810251 9354454
4	SOX10	SRY-Box Transcription Factor 10	Protein Coding	28.87	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16036108 16510576 18636017
5	S100A1	S100 Calcium Binding Protein A1	Protein Coding	28.21	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	18547346 1803052 11536443 (more) 16481232 19154261
6	PDGFRA	Platelet Derived Growth Factor Receptor Alpha	Protein Coding	27.74	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16357008 14673600 18281533 (more) 17558420
7	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	27.71	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	14508395 12152785 10469453 (more) 11406645 10595918 10595915 14519636 16540739 15715079 14722917 15207265 12812137
8	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	25.53	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16357008 16481232 16235251 (more) 11865845
9	TOP2A	DNA Topoisomerase II Alpha	Protein Coding	25.26	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	14673046 16721726 14508395 (more) 18522746
10	S100B	S100 Calcium Binding Protein B	Protein Coding	24.07	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11145248 11732802 17119986 (more) 18480004 18636017 20025639 15774214 14508395 11580072 10584703 17910355 7645984 10891546 11438454 18547346
11	NRG1	Neuregulin 1	Protein Coding	23.54	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15897877 12838503 19306381 (more) 15015657
12	EGFR	Epidermal Growth Factor Receptor	Protein Coding	19.97	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10791998 18650488 19330289 (more) 19921253 18448562 12152785 17235305 19948538
13	MYOG	Myogenin	Protein Coding	17.95	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11688574
14	ACTC1	Actin Alpha Cardiac Muscle 1	Protein Coding	17.55	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16481232
15	CD34	CD34 Molecule	Protein Coding	17.33	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9092861 12692193
16	CD44	CD44 Molecule (Indian Blood Group)	Protein Coding	15.93	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12730955 9354454
17	MET	MET Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	15.88	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	14730703 11477120
18	MDM2	MDM2 Proto-Oncogene	Protein Coding	15.3	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11493336 11406645 7551341 (more) 10469453 17146434 16818505
19	TP53	Tumor Protein P53	Protein Coding	14.79	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
20	MMP13	Matrix Metallopeptidase 13	Protein Coding	13.76	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17786186 14673600 18281533
21	S100A6	S100 Calcium Binding Protein A6	Protein Coding	13.75	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18201235 18547346
22	NGFR	Nerve Growth Factor Receptor	Protein Coding	13.53	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16510576 16528378
23	B3GAT1	Beta-1,3-Glucuronyltransferase 1	Protein Coding	13.09	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
24	PDGFRB	Platelet Derived Growth Factor Receptor Beta	Protein Coding	12.92	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
25	KRT7	Keratin 7	Protein Coding	12.9	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
26	MITF	Melanocyte Inducing Transcription Factor	Protein Coding	12.19	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11145252
27	KRT19	Keratin 19	Protein Coding	11.86	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
28	TERT	Telomerase Reverse Transcriptase	Protein Coding	11.76	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18069666
29	KDM4B	Lysine Demethylase 4B	Protein Coding	11.67	DISEASES inferred ¹⁴ GeneCards inferred via : Summaries (show sections)
30	HGF	Hepatocyte Growth Factor	Protein Coding	11.36	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
31	NES	Nestin	Protein Coding	11.13	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16528378 11238030 17300669
32	PMP22	Peripheral Myelin Protein 22	Protein Coding	10.54	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
33	CDKN2B	Cyclin Dependent Kinase Inhibitor 2B	Protein Coding	10.45	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	14519636 10469453
34	HGFAC	HGF Activator	Protein Coding	10.37	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
35	CDK4	Cyclin Dependent Kinase 4	Protein Coding	9.01	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10469453

Sources

Variations for Malignant Peripheral Nerve Sheath Tumor

Cosmic variations for Malignant Peripheral Nerve Sheath Tumor:

⁸ (show top 50) (show all 604)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM143156898	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.376G>A	p.E126K	17:7673767-7673767	12
2	COSM111758616	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.713G>A	p.C238Y	17:7674250-7674250	12
3	COSM143384267	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.656A>C	p.E219A	17:7674190-7674190	12
4	COSM105621014	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.96+1G>A	p.?	17:7676381-7676381	12
5	COSM142581311	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.704T>C	p.V235A	17:7673799-7673799	12
6	COSM142560073	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.542A>G	p.Y181C	17:7674872-7674872	12
7	COSM106053265	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.853G>A	p.E285K	17:7673767-7673767	12
8	COSM144316114	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.400G>A	p.V134M	17:7675095-7675095	12
9	COSM143370705	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.542A>G	p.Y181C	17:7674872-7674872	12
10	COSM121876031	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.317G>A	p.C106Y	17:7674250-7674250	12
11	COSM93183674	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.713G>A	p.C238Y	17:7674250-7674250	12
12	COSM144651221	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.736G>A	p.E246K	17:7673767-7673767	12
13	COSM143156869	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.236G>A	p.C79Y	17:7674250-7674250	12
14	COSM111780488	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.821T>C	p.V274A	17:7673799-7673799	12
15	COSM105620321	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.713G>A	p.C238Y	17:7674250-7674250	12
16	COSM142838860	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.833C>A	p.P278H	17:7673787-7673787	12
17	COSM93185679	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.833C>A	p.P278H	17:7673787-7673787	12
18	COSM112254242	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.96+1G>A	p.?	17:7676381-7676381	12
19	COSM144013959	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.502C>T	p.H168Y	17:7675077-7675077	12
20	COSM144033042	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.788T>C	p.V263A	17:7673799-7673799	12
21	COSM122278673	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.121G>A	p.V41M	17:7675095-7675095	12
22	COSM122271391	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.263A>G	p.Y88C	17:7674872-7674872	12
23	COSM111762096	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.832C>G	p.P278A	17:7673788-7673788	12
24	COSM143370962	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.736G>A	p.E246K	17:7673767-7673767	12
25	COSM145029562	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.656A>C	p.E219A	17:7674190-7674190	12
26	COSM143162941	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.40G>A	p.V14M	17:7675095-7675095	12
27	COSM106053184	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.829T>G	p.C277G	17:7673791-7673791	12
28	COSM143943833	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.236G>A	p.C79Y	17:7674250-7674250	12
29	COSM105622587	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.782+394C>A	p.?	17:7673787-7673787	12
30	COSM143159469	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.355C>G	p.P119A	17:7673788-7673788	12
31	COSM143373039	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.716C>A	p.P239H	17:7673787-7673787	12
32	COSM122744599	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.565A>T	p.K189*	17:7673567-7673567	12
33	COSM87898343	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.829T>G	p.C277G	17:7673791-7673791	12
34	COSM143370860	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.712T>G	p.C238G	17:7673791-7673791	12
35	COSM87900710	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.833C>A	p.P278H	17:7673787-7673787	12
36	COSM143944441	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.58C>T	p.H20Y	17:7675077-7675077	12
37	COSM106053221	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.713G>A	p.C238Y	17:7674250-7674250	12
38	COSM144651747	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.418C>T	p.H140Y	17:7675077-7675077	12
39	COSM144013358	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.796T>G	p.C266G	17:7673791-7673791	12
40	COSM143156731	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.182A>G	p.Y61C	17:7674872-7674872	12
41	COSM112264430	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.961A>T	p.K321*	17:7673567-7673567	12
42	COSM143963152	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.344T>C	p.V115A	17:7673799-7673799	12
43	COSM145028698	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.844A>T	p.K282*	17:7673567-7673567	12
44	COSM144327798	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.704T>C	p.V235A	17:7673799-7673799	12
45	COSM142570943	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.844A>T	p.K282*	17:7673567-7673567	12
46	COSM112256366	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.832C>G	p.P278A	17:7673788-7673788	12
47	COSM112254176	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.535C>T	p.H179Y	17:7675077-7675077	12
48	COSM93195964	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.773A>C	p.E258A	17:7674190-7674190	12
49	COSM111771883	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.773A>C	p.E258A	17:7674190-7674190	12
50	COSM145025304	TP53	soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS	c.400G>A	p.V134M	17:7675095-7675095	12

Copy number variations for Malignant Peripheral Nerve Sheath Tumor from CNVD:

⁶ (show all 45)

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	17387	1	142600000	147000000	Gain		Malignant peripheral nerve sheath tumor
2	22132	1	165500000	170900000	Gain		Malignant peripheral nerve sheath tumor
3	23047	1	170900000	176000000	Gain		Malignant peripheral nerve sheath tumor
4	49109	11	102900000	112500000	Loss		Malignant peripheral nerve sheath tumor
5	49995	11	112500000	121200000	Loss		Malignant peripheral nerve sheath tumor
6	53584	11	31000000	36400000	Loss		Malignant peripheral nerve sheath tumor
7	61507	12	1	3100000	Gain	FOXM1	Malignant peripheral nerve sheath tumor
8	65742	12	21200000	26300000	Amplification	SOX5	Malignant peripheral nerve sheath tumor
9	66816	12	3300000	10100000	Gain		Malignant peripheral nerve sheath tumor
10	67235	12	38200000	49100000	Gain		Malignant peripheral nerve sheath tumor
11	69080	12	5300000	10000000	Gain	NOP2	Malignant peripheral nerve sheath tumor
12	69882	12	56428269	56432431	Gain	CDK4	Malignant peripheral nerve sheath tumor
13	69960	12	56600000	71500000	Gain		Malignant peripheral nerve sheath tumor
14	71535	12	71500000	86700000	Gain		Malignant peripheral nerve sheath tumor
15	73254	12	92600000	109000000	Gain		Malignant peripheral nerve sheath tumor
16	73259	12	92600000	96200000	Gain		Malignant peripheral nerve sheath tumor
17	75380	13	19500000	25500000	Gain		Malignant peripheral nerve sheath tumor
18	76637	13	34000000	55300000	Gain		Malignant peripheral nerve sheath tumor
19	79536	13	73300000	77200000	Gain		Malignant peripheral nerve sheath tumor
20	85488	14	47200000	67900000	Loss		Malignant peripheral nerve sheath tumor
21	87451	14	73800000	107349540	Gain		Malignant peripheral nerve sheath tumor
22	97234	16	1	10500000	Gain		Malignant peripheral nerve sheath tumor
23	102841	16	57400000	90354753	Gain		Malignant peripheral nerve sheath tumor
24	105377	16	7900000	14800000	Gain		Malignant peripheral nerve sheath tumor
25	115613	17	58300000	81195210	Gain		Malignant peripheral nerve sheath tumor
26	124065	19	1	13900000	Gain		Malignant peripheral nerve sheath tumor
27	147242	2	61300000	68600000	Gain		Malignant peripheral nerve sheath tumor
28	150135	2	96800000	114400000	Gain		Malignant peripheral nerve sheath tumor
29	163892	22	32200000	44200000	Gain		Malignant peripheral nerve sheath tumor
30	172609	3	184500000	198022430	Gain		Malignant peripheral nerve sheath tumor
31	174546	3	2800000	16400000	Gain		Malignant peripheral nerve sheath tumor
32	175421	3	39400000	54400000	Gain		Malignant peripheral nerve sheath tumor
33	196162	5	159900000	180915260	Gain		Malignant peripheral nerve sheath tumor
34	198008	5	18400000	23300000	Gain		Malignant peripheral nerve sheath tumor
35	209673	6	27000000	57000000	Gain		Malignant peripheral nerve sheath tumor
36	213890	6	52900000	70000000	Gain		Malignant peripheral nerve sheath tumor
37	220382	7	13800000	43300000	Gain		Malignant peripheral nerve sheath tumor
38	227906	7	72200000	86400000	Gain		Malignant peripheral nerve sheath tumor
39	240607	8	52600000	146364022	Gain		Malignant peripheral nerve sheath tumor
40	241476	8	6200000	36500000	Gain		Malignant peripheral nerve sheath tumor
41	244863	9	1	14200000	Gain		Malignant peripheral nerve sheath tumor
42	247559	9	130300000	135900000	Gain		Malignant peripheral nerve sheath tumor
43	249423	9	14200000	28000000	Loss		Malignant peripheral nerve sheath tumor
44	255080	9	72339785	73251640	Dramatically overexpressed,genomicallyamplified	TRPM3	Malignant peripheral nerve sheath tumor
45	255774	9	84100000	102600000	Gain		Malignant peripheral nerve sheath tumor

Sources

Expression for Malignant Peripheral Nerve Sheath Tumor

Search GEO for disease gene expression data for Malignant Peripheral Nerve Sheath Tumor.

Sources

Pathways for Malignant Peripheral Nerve Sheath Tumor

Pathways related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

(show top 50) (show all 51)

#	Super pathways	Score	Top Affiliating Genes
1	Apoptotic Pathways in Synovial Fibroblasts ⁶⁴ Show member pathways Actin-Based Motility by Rho Family GTPases ⁶⁴ Cellular Apoptosis Pathway ⁶⁴ DHA Signaling ⁶⁴ eIF2 Pathway ⁶⁴ ERK5 Signaling ⁶⁴ Glioma Invasiveness ⁶⁴ Mitochondrial Apoptosis ⁶⁴ Nuclear Receptor Activation by Vitamin-A ⁶⁴ p53 Mediated Apoptosis ⁶⁴ PPAR Pathway ⁶⁴ Rac1 Pathway ⁶⁴ Rap1 Pathway ⁶⁴ Telomerase Components in Cell Signaling ⁶⁴	13.83	TP53 PDGFRA NRG1 MET MDM2 KIT
2	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.8	TP53 S100A1 PDGFRA NRG1 NF1 MET
3	GPCR Pathway ⁶⁴ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁴ Estrogen Pathway ⁶⁴ NFAT in Immune Response ⁶⁴ P2Y Receptor Signaling ⁶⁴ Pancreatic Adenocarcinoma ⁶⁴ Paxillin Interactions ⁶⁴ Ras Pathway ⁶⁴	13.69	CDKN2A EGFR KIT MDM2 MET MMP13
4	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.67	VIM TP53 SOX10 PDGFRA NRG1 NF1
5	Signal Transduction ⁶⁶	13.45	ACTC1 EGFR KIT MDM2 MET NF1
6	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.4	TP53 PDGFRA NRG1 MET MDM2 KIT
7	Prolactin Signaling ⁶⁴ Show member pathways Development Prolactin receptor signaling ²² EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ⁷⁴ ErbB Family Pathway ⁶⁴ ErbB signaling pathway ⁷⁴ ErbB2-ErbB3 Heterodimers ⁶⁴ ErbB4 Pathway ⁶⁴ Estrogen-stimulated signaling through PRKCZ ⁶⁶ Glioblastoma Multiforme ⁶⁴ Glioblastoma signaling pathways ⁷⁴ Growth Hormone Signaling ⁶⁴ HMGB1 Pathway ⁶⁴ IL-2 Pathway ⁶⁴ LPS Stimulated MAPK Signaling ⁶⁴ PACAP Signaling ⁶⁴ PI3K Signaling in B-Lymphocyte ⁶⁴ TCA cycle nutrient use and invasiveness of ovarian cancer ⁷⁴ Thrombopoietin Pathway ⁶⁴ TREM1 Pathway ⁶⁴ UVA-Induced MAPK Signaling ⁶⁴ UVB-Induced MAPK Signaling ⁶⁴ UVC-Induced MAPK Signaling ⁶⁴	13.38	TP53 PDGFRA NRG1 NF2 NF1 MET
8	RAF/MAP kinase cascade ⁶⁶ Show member pathways Diseases of signal transduction by growth factor receptors and second messengers ⁶⁶ MAPK family signaling cascades ⁶⁶ MAPK1/MAPK3 signaling ⁶⁶	13.36	EGFR KIT MDM2 MET NF1 NRG1
9	PIP3 activates AKT signaling ⁶⁶ Show member pathways Intracellular signaling by second messengers ⁶⁶ PTEN Regulation ⁶⁶ Regulation of PTEN gene transcription ⁶⁶ Regulation of PTEN localization ⁶⁶	13.02	TP53 PDGFRA NRG1 MET MDM2 KIT
10	Phospholipase-C Pathway ⁶⁴ Show member pathways PTEN Pathway ⁶⁴	13.01	EGFR KIT MDM2 MET NRG1 PDGFRA
11	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	12.95	TP53 PDGFRA MET MDM2 KIT EGFR
12	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.81	EGFR KIT MET NRG1 PDGFRA S100B
13	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.63	EGFR KIT MET NRG1 PDGFRA TP53
14	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.61	TP53 NF1 MDM2 KIT EGFR CDKN2A
15	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ⁶⁶ Show member pathways Constitutive Signaling by Aberrant PI3K in Cancer ⁶⁶ Negative regulation of the PI3K/AKT network ⁶⁶ PI3K/AKT Signaling in Cancer ⁶⁶	12.58	PDGFRA NRG1 MET MDM2 KIT EGFR
16	DNA Damage ³	12.5	VIM TP53 TOP2A MDM2 CDKN2A
17	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.48	TP53 NRG1 MDM2 EGFR
18	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.43	TP53 PDGFRA MDM2 KIT EGFR
19	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.4	TP53 PDGFRA MET MDM2 EGFR
20	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.37	PDGFRA NRG1 MET KIT EGFR
21	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.2	TP53 PDGFRA MET MDM2 EGFR
22	Integrated breast cancer pathway ⁷⁴	12.14	TP53 NF1 MDM2 EGFR
23	Ras signaling ⁷⁴	12.14	EGFR KIT MET NF1 PDGFRA
24	mTOR Signaling ⁶⁵	12.1	TP53 PDGFRA MET EGFR
25	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ⁶¹ Nuclear signaling by ERBB4 ⁶⁶	12.07	S100B NRG1 MDM2 EGFR
26	Direct p53 effectors ⁶¹	12.05	TP53 MET MDM2 EGFR
27	Tyrosine Kinases / Adaptors ³	11.97	PDGFRA NRG1 MET KIT EGFR
28	Gastrin signaling pathway ⁷⁴	11.96	KIT EGFR CDKN2A CD44
29	Malignant pleural mesothelioma ⁷⁴	11.93	TP53 PDGFRA NF2 MET MDM2 KIT
30	Senescence and autophagy in cancer ⁷⁴	11.91	TP53 MDM2 CDKN2A CD44
31	Mesenchymal Stem Cells and Lineage-specific Markers ⁶⁵	11.84	MYOG KIT CD44 CD34
32	Retinoblastoma gene in cancer ⁷⁴	11.82	TP53 TOP2A MDM2
33	Innate Lymphoid Cells Differentiation ⁶⁵	11.78	KIT CD44 CD34
34	C-MYB transcription factor network ⁶¹	11.78	KIT CDKN2A CD34
35	Regulation of TP53 Expression and Degradation ⁶⁶ Show member pathways Regulation of TP53 Degradation ⁶⁶ Regulation of TP53 Expression ⁶⁶	11.75	TP53 MDM2 CDKN2A
36	Head and neck squamous cell carcinoma ⁷⁴	11.73	TP53 EGFR CDKN2A
37	Cell adhesion_ECM remodeling ²²	11.65	MMP13 EGFR CD44
38	Regulation of retinoblastoma protein ⁶¹	11.61	MET MDM2 CDKN2A
39	Proteolysis Putative SUMO-1 pathway ²² Show member pathways DNA damage Role of SUMO in p53 regulation ²²	11.59	TP53 TOP2A MDM2
40	HIF1Alpha Pathway ⁶⁴	11.58	TP53 MDM2 CDKN2A
41	p53 pathway ⁶¹	11.55	TP53 MDM2 CDKN2A
42	Cardiac progenitor differentiation ⁷⁴	11.46	PDGFRA NRG1 KIT ACTC1
43	Neural Stem Cells and Lineage-specific Markers ⁶⁵	11.45	VIM SOX10 S100B PDGFRA CD44
44	Hippo-Merlin signaling dysregulation ⁷⁴ Show member pathways Hippo signaling regulation pathways ⁷⁴	11.39	PDGFRA NF2 MET KIT EGFR CD44
45	Validated transcriptional targets of deltaNp63 isoforms ⁶¹	11.34	TOP2A NRG1 MDM2 CDKN2A
46	Oncogene Induced Senescence ⁶⁶	11.33	TP53 MDM2 CDKN2A
47	Gastric cancer network 2 ⁷⁴	11.29	TP53 TOP2A EGFR
48	Bladder cancer ⁷⁴	11.22	TP53 MDM2 EGFR CDKN2A
49	Inhibition of Ribosome Biogenesis by p14(ARF) ⁶⁴	11.07	TP53 MDM2 CDKN2A
50	G-protein signaling_Rap2B regulation pathway ²²	11.01	VIM PDGFRA NRG1 MET KIT EGFR

Sources

GO Terms for Malignant Peripheral Nerve Sheath Tumor

Cellular components related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	plasma membrane	GO:0005886	9.64	PDGFRA NRG1 MET KIT EGFR CD44
2	plasma membrane	GO:0005887	9.64	PDGFRA NRG1 MET KIT EGFR CD44

Biological processes related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

(show all 18)

#	Name	GO ID	Score	Top Affiliating Genes
1	regulation of cell cycle	GO:0051726	10.25	TP53 NF2 MYOG MDM2 CDKN2A
2	transmembrane receptor protein tyrosine kinase signaling pathway	GO:0007169	10.16	PDGFRA MET KIT EGFR
3	MAPK cascade	GO:0000165	10.11	NRG1 NF2 NF1 EGFR
4	hematopoietic progenitor cell differentiation	GO:0002244	10.01	TP53 TOP2A PDGFRA KIT
5	neuroblast proliferation	GO:0007405	10	TP53 SOX10 NF1
6	oligodendrocyte differentiation	GO:0048709	9.93	NF1 NRG1 SOX10
7	peripheral nervous system development	GO:0007422	9.88	SOX10 NRG1 NF1
8	negative regulation of cell-matrix adhesion	GO:0001953	9.85	NF2 NF1 CDKN2A
9	cell population proliferation	GO:0008283	9.83	EGFR KIT NF1 NRG1 TP53
10	cellular response to actinomycin D	GO:0072717	9.81	TP53 MDM2
11	mast cell proliferation	GO:0070662	9.8	NF1 KIT
12	Schwann cell proliferation	GO:0014010	9.76	NF2 NF1
13	regulation of cell population proliferation	GO:0042127	9.73	TP53 NF2 NF1 KIT EGFR
14	positive regulation of gene expression	GO:0010628	9.73	VIM TP53 SOX10 NRG1 KIT CDKN2A
15	negative regulation of Schwann cell proliferation	GO:0010626	9.63	NF1 NF2 SOX10
16	multicellular organism development	GO:0007275	9.62	PDGFRA MET KIT EGFR
17	positive regulation of miRNA maturation	GO:1903800	9.58	TP53 EGFR
18	positive regulation of kinase activity	GO:0033674	9.28	PDGFRA MET KIT EGFR CD44

Molecular functions related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein tyrosine kinase activity	GO:0004713	9.7	PDGFRA MET KIT EGFR
2	disordered domain specific binding	GO:0097718	9.35	TP53 MDM2 CDKN2A
3	transmembrane receptor protein tyrosine kinase activity	GO:0004714	9.23	PDGFRA MET KIT EGFR